Company news
Geovax Labs, Inc. (NASDAQ:GOVX) news
Every Geovax Labs, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation
August 25, 2026
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit
August 20, 2026
GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Bas...
August 3, 2026
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update
July 27, 2026
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy
July 21, 2026
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses
June 8, 2026
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
June 3, 2026
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness
June 1, 2026
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
May 26, 2026
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
May 20, 2026
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
May 18, 2026
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
May 6, 2026
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities
April 29, 2026
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
April 15, 2026
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
April 14, 2026
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
April 2, 2026
GeoVax Announces a Warrant Inducement Transaction
March 31, 2026
GeoVax Provides Update on GEO-MVA Program
March 25, 2026
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocomprom...
March 12, 2026
GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox Vaccine
March 11, 2026
GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid Tumors
February 24, 2026
GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination Technology
February 18, 2026
GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 13, 2026
GeoVax Highlights 2026 as a Pivotal Year for Progress
January 20, 2026
GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
January 8, 2026
GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week
January 6, 2026
GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering
December 19, 2025
GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine
December 18, 2025
GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA
December 18, 2025
GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026
December 17, 2025
GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design
December 16, 2025
GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients
December 15, 2025
GeoVax Addresses Identification of New Mpox Variant
December 11, 2025
GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board
December 10, 2025
GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy
December 9, 2025
GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recu...
December 8, 2025
GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference
November 24, 2025
GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update
November 13, 2025
GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination
November 10, 2025
GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025
November 4, 2025
GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement
November 3, 2025
BIO CEO Warns U.S. Could Lose Biotech Leadership Within Two Years; GeoVax Calls on Congress and Administration to Act Now
October 30, 2025
GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients With Recent Clinical Data for GEO-CM04S1
October 29, 2025
GeoVax Welcomes New IDSA Guidance Highlighting Need for Tailored COVID-19 Vaccines for Immunocompromised Patients
October 28, 2025
GeoVax Highlights Urgent Need for Multisource Mpox Vaccine Supply Following California Clade 1 Cases
October 20, 2025
GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Eur...
October 16, 2025
GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions
October 13, 2025
GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025
October 9, 2025
GeoVax to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
October 7, 2025
GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity Summit
October 1, 2025